Atlas Trials

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Clinical trial NCT06069726 · RECRUITING

Trial details

NCT number
NCT06069726
Sponsor
Duke University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2024-03-21
Primary completion
2028-01-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.